Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 5, 2024PharmaceuticalsOpen Access

Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study

View Full Paper
Ask AI
Bookmark
Share

Authors

ZGZihan GuoYDYunlan DingMWMengmeng Wang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Guo et al. (2024) studied this question.

synapsesocial.com/papers/68e5d588b6db64358756be88https://doi.org/10.3390/ph17081025
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)2019 · 357 citations
  2. 2Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia2018 · 5,819 citations
  3. 3Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma2021 · 2,564 citations
  4. 4Clinical development of CAR T cell therapy in China: 2020 update2020 · 88 citations
  5. 5Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial2018 · 2,301 citations